End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.76 CNY | +1.45% | -5.31% | +2.26% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 66% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- Revenue estimates are regularly revised downwards for the current and coming years.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.26% | 1.06B | - | ||
-11.83% | 79.26B | B+ | ||
+15.37% | 8.39B | B- | ||
+28.00% | 3.74B | B- | ||
-1.39% | 3.27B | B- | ||
+21.28% | 1.69B | - | ||
-3.25% | 1.56B | B | ||
-18.63% | 1.29B | C- | ||
-1.17% | 1.28B | - | ||
-6.77% | 1.14B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300119 Stock
- Ratings Tianjin Ringpu Bio-Technology Co.,Ltd.